Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company (the “Company”), was notified on September 23, 2011 by U.S. Trust, Bank of America Private Wealth Management that they had on September 1, 2011, under a discretionary international portfolio managed for Kevin Rakin, acquired 25 Shire American Depositary Shares at a price of $96.81 each (the “Shares”).
In addition, the Company was notified that on September 22, 2011, the Shares were sold at a price of $90.76 each. One Shire American Depositary Share is equal to three Shire ordinary shares.
This notification relates to disclosures made in accordance with 3.1.4(R)(1)(a) of the Disclosure Rules and Transparency Rules.
Deputy Company Secretary
For further information please contact:
|Investor Relations||Eric Rojas
|+1 781 482 0999|
|+44 1256 894157|
Notes to editors
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder, human genetic therapies, gastrointestinal diseases and regenerative medicine as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.